A clinical update on ulcerative colitis for primary care

Ulcerative colitis (UC) is a type of chronic, relapsing inflammatory bowel disease (IBD) characterized by mucosal inflammation of the colon and rectum. Symptoms such as bloody diarrhea, abdominal pain, and fecal urgency significantly affect patient quality of life. Early recognition of UC is critical to facilitate specialist referral and initiate management. Recent advances in the therapeutic landscape include the introduction of novel biologic agents, small molecules, and biosimilars, which have expanded access to effective and affordable treatment options. Clinicians must remain informed of updates and indications for both pharmacologic and nonpharmacologic interventions, as treatment selection is based on disease severity, location, and individualized patient needs. Adjunctive therapies also play a role in comprehensive care and health maintenance. Optimizing therapy is essential for inducing and maintaining remission, promoting mucosal healing, and preventing disease progression. A multidisciplinary approach, involving primary care clinicians, gastroenterologists, colorectal surgeons, dietitians, and mental health professionals, is essential for delivering individualized care and improving long-term outcomes.

Authors

Institutions

Publication Details

Journal
JAAPA
Published
2026-02-24
DOI
https://doi.org/10.1097/01.jaa.0000000000000324
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A clinical update on ulcerative colitis for primary care

Sarah Bolander, Kimberly Carter, Nicole Hamilton, Tiffany Cooke
JAAPA
Inflammatory Bowel Disease
article

A clinical update on ulcerative colitis for primary care

Sarah Bolander, Kimberly Carter, Nicole Hamilton, Tiffany Cooke
article en

Abstract

Ulcerative colitis (UC) is a type of chronic, relapsing inflammatory bowel disease (IBD) characterized by mucosal inflammation of the colon and rectum. Symptoms such as bloody diarrhea, abdominal pain, and fecal urgency significantly affect patient quality of life. Early recognition of UC is critical to facilitate specialist referral and initiate management. Recent advances in the therapeutic landscape include the introduction of novel biologic agents, small molecules, and biosimilars, which have expanded access to effective and affordable treatment options. Clinicians must remain informed of updates and indications for both pharmacologic and nonpharmacologic interventions, as treatment selection is based on disease severity, location, and individualized patient needs. Adjunctive therapies also play a role in comprehensive care and health maintenance. Optimizing therapy is essential for inducing and maintaining remission, promoting mucosal healing, and preventing disease progression. A multidisciplinary approach, involving primary care clinicians, gastroenterologists, colorectal surgeons, dietitians, and mental health professionals, is essential for delivering individualized care and improving long-term outcomes.

JAAPAVol. 39(3)
Midwestern University (US), Chongqing Electromechanical Holdings (China) (CN)
Openalex Percentile: Top 44%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.